MedTrace Logo

Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

NCT00803868 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-07-24

No results posted yet for this study

Summary

The purpose of this study is to determine if varenicline is effective in treating symptoms of Friedreich's ataxia.

Conditions

Interventions

DRUG

varenicline

up to 1mg po bid for 9 weeks

DRUG

placebo

placebo matching study drug up to 1mg po bid

Sponsors & Collaborators

  • Friedreich's Ataxia Research Alliance

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • University of South Florida

    lead OTHER

Principal Investigators

  • Theresa Zesiewicz, M.D. · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803868 on ClinicalTrials.gov